Consistent with its current practice, Zymeworks does not plan to host a conference call or webcast for its third quarter 2026 financial results. Management looks forward to engaging with the ...
The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-6184 International Investors: 201-389-0877 Conference ID: 13762954 ...
As an ISO/IEC 17024 accredited certification body, EC-Council's credentials are recognized by the U.S. Department of Defense under DoD 8140 and are held by professionals across the U.S. Army, Navy and ...
"AABB sets the standards for biobanking and cellular therapy, so having this community recognize our work as a Top Poster means a great deal to our team," said Kevin Caldwell, CEO, Co-Founder & ...
The inducement grant consists of non-qualified stock options to purchase 200,000 shares of common stock at an exercise price of $0.86 per share, which is equal to the closing price of the Company’s ...
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...
These MAA submissions in addition to NDA submissions in the U.S. with Priority Review and Japan under the SAKIGAKE Designation System for accelerated review, support Belite’s mission of building a ...
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on ...
NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2026 results on Wednesday, October 28, ...
PARSIPPANY, NJ, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced that it expects preliminary, unaudited revenue for the third ...
LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results